-
Standardized Whole-Blood Stimulation and Immunometabolism
2026-09-29
The reference study presents a standardized whole-blood stimulation protocol for measuring how metabolic interventions shape cytokine responses to innate immune and microbial stimuli. Its main contribution is a reproducible framework that preserves the complexity of human blood while enabling controlled analysis of immunometabolic regulation in cohort and translational studies.
-
KCNE4-Dependent Modulation of Kv1.3 Pharmacology
2026-09-29
The reference study shows that KCNE4 changes the functional pharmacology of Kv1.3 without measurably changing the apparent affinity of either margatoxin or Psora 4. Its principal effect is to slow Psora 4-mediated inhibition in a stoichiometry-dependent manner, indicating that regulatory-subunit architecture must be considered when interpreting Kv1.3 blocker assays in leukocyte research.
-
Rapamycin: mTOR Workflows for Lipotoxicity Research
2026-09-28
Rapamycin (Sirolimus) enables a controlled test of whether mTORC1 drives lipid-induced hepatocyte dysfunction, triglyceride secretion, and cell death. This workflow combines dose-aware pathway inhibition with lipid-matched controls, orthogonal readouts, and troubleshooting guidance for translating mTOR biology into reproducible assays.
-
WDR36 Links Glycolysis to Human TE Differentiation
2026-09-28
The study uses human stem cell-derived blastoids to show that WDR36 is required for efficient trophectoderm lineage commitment and connects this function to glycolysis, including an interaction with LDHA. The findings extend earlier mouse observations while remaining a model-based, preclinical account of early human development.
-
WDR36, Glycolysis, and Early Lineage Decisions
2026-09-27
A translational perspective on how WDR36-linked glucose metabolism may shape trophectoderm commitment in human blastoid models—and how to turn that finding into a rigorous experimental strategy.
-
MK-0812 for CCR2 Studies in MASH Models
2026-09-26
Use MK-0812 to test whether CCR2-dependent monocyte trafficking contributes to liver inflammation in gut–liver axis models—not to assume it blocks the TM6SF2–LPA mechanism itself. Its reported nanomolar activity supports a focused in vitro workflow, while careful controls can distinguish immune-cell recruitment from changes in barrier function, microbiota, or lipid signaling.
-
Ginkgo Compound Cocktail Supports Yeast Longevity
2026-09-25
A network pharmacology-guided cocktail of four Ginkgo biloba compounds improved chronological lifespan and mitochondrial measures in yeast, while reducing reactive oxygen species. The study illustrates how combining chemical profiling with functional testing can narrow a complex botanical extract to a testable mixture, although the findings remain specific to yeast and require validation in other models.
-
IL-7, human recombinant: Assay Design Guide
2026-09-25
Practical guidance for evaluating IL-7, human recombinant (SKU P1024) in lymphocyte viability, proliferation, and cytotoxicity workflows. It separates sound assay-design recommendations from product-specific details that are not provided, so researchers can select controls and request the information needed for reproducible experiments.
-
Partial BACE Inhibition Preserves Synaptic Transmission
2026-09-24
Satir et al. tested whether reducing amyloid-β production with β-secretase inhibitors necessarily impairs synaptic transmission. In cultured rat cortical neurons, partial inhibition that lowered secreted amyloid-β by less than 50% did not reduce the measured synaptic signal, highlighting a potential exposure range for further study rather than establishing a clinical treatment strategy.
-
Isochlorogenic Acid A: Interpreting Hydrogel Evidence
2026-09-24
Isochlorogenic acid A (3,5-Dicaffeoylquinic acid) is more than a candidate bioactive: its delivery format can shape what an experiment actually measures. This evidence-focused guide separates compound effects from hydrogel and nanoparticle effects to support clearer wound-repair research decisions.
-
Ruxolitinib phosphate: ATC Assay Workflow
2026-09-23
Use Ruxolitinib phosphate to test how JAK1/2 inhibition connects STAT3 activity with mitochondrial dynamics and cell death in anaplastic thyroid cancer models. This workflow pairs pathway readouts with apoptosis, pyroptosis, and mitochondrial assays, while distinguishing proposed starting conditions from findings reported in the literature.
-
PHF2 Links Neuroinflammation to Alzheimer’s Memory Loss
2026-09-23
A 2025 Molecular Psychiatry study identifies the histone demethylase PHF2 as an epigenetic regulator of inflammatory gene expression in Alzheimer’s disease. By combining human tissue, patient-derived neurons, chromatin profiling, genetic perturbation, and behavioral testing, the work connects PHF2 activity with glial activation, synaptic dysfunction, and spatial memory impairment.
-
AI-10-49 for CBFβ-SMMHC AML Research
2026-09-22
AI-10-49 enables mechanism-led studies of RUNX1 displacement, chromatin recovery, and downstream MYCN/eIF4G1 biology in inv(16) leukemia. This practical guide connects target engagement, leukemia cell proliferation inhibition, chromatin immunoprecipitation assay design, and in vivo validation while emphasizing controls and formulation consistency.
-
SB 431542: ALK5 Inhibitor Workflow
2026-09-22
SB 431542 offers a practical way to separate ALK5-driven TGF-β responses from downstream phenotype changes in fibrosis, cancer, and immune-cell assays. This workflow combines pathway-level validation, phenotype controls, formulation guidance, and troubleshooting for reproducible experiments.
-
Myriocin: From SPT Blockade to Metabolic Insight
2026-09-21
Myriocin is a selective serine palmitoyltransferase inhibitor that connects sphingolipid flux with glucose, lipid, and mitochondrial regulation. This evidence-led guide translates a 2025 mouse study into practical assay decisions while distinguishing metabolic findings from oncology applications.